DoP invites nominations for 5th India Pharma and Medical Device Awards
New Delhi: The Government of India, Ministry of Chemicals & Fertilizers, Department of Pharmaceuticals (DoP) has decided to confer 5th India Pharma/Medical Device Awards during India Pharma 2020 & India Medical Device 2020.
In this regard, DoP has invited nominations for the various categories. The last date for receipt of nominations is 20th November 2019. No nomination will be accepted after the last date.
Nominees can send separate nominations for each category along with supporting documents to N. K Joshi, Under Secretary to the Government of India, Tel: 23383392, Email:- navin.26@nic.in.
The categories under which the awards will be granted are;
Criteria/Indicators for India Pharma and India Medical Device Awards
1. India Pharma Leader Award
| S.No | Criteria | Indicators | Relevant information/ Documents to be furnished. |
| a. | Sales Turnover Growth in %(25% weightage) | - Cumulative growth over last 3 years i.e. % increase in sale in Year 3 as compared to Year 1. -Highest of all entries received to have full marks and others proportionate | Audited sales' figures for the last three financial years, duly certified by Company Secretary. |
| b. | Turnover of manufacturing in own plants as a Percentage of total turnover (25% weightage) | - Highest of all entries received to have full marks and others proportionate | Audited figures on item wise production in terms of quantity and value for different Pharma products manufactured in their own manufacturing facilities, in the previous year duly certified by Company Secretary |
| c. | Percentage of Sales of NLEMs vis-a-vis total Sales of Pharma products (20% weightage) | - Highest of all entries received to have full marks and others proportionate | Audited figures of sales of NLEMs for last financial year, duly certified by Company Secretary |
| d. | Number of products launched in the last year (10% weightage) | - Highest of all entries received to have full marks and others proportionate | List of products launched in the last year, duly certified by the Company Secretary. |
| e | Percentage of expenditure on R&D vis-a-vis total Annual Sales turnover averaged over 3 years (20% weightage) | - Highest of all entries received to have full marks and others proportionate | Audited figures of expenditure on R&D incurred as a % of total sales, during last 3 financial years, duly certified by Company Secretary |
A one page brief about the company along with a name of important products being produced and its therapeutic significance
2. India Pharma Bulk Drug Company of the Year Award
| S.No | Criteria | Indicators | Relevant information/ Documents to be furnished. |
| a. | Increase in Sales in % terms over the previous year (40% weightage) | - Highest of all entries received to have full marks and others proportionate | The Company should indicate item-wise production and sales of Bulk Drugs in last 2 financial years duly certified by Company Secretary. |
| b. | Sales of Bulk Drugs, for use in the manufacture of NLEM drugs as a percentage of total sales (30% weightage) | - Highest of all entries received to have full marks and others proportionate | List of Bulk Drugs, together with item-wise production and sales figures, which are used in the production of NLEMs, for the last financial year, duly certified by Company Secretary |
| c. | Increase in R&D expenditure on bulk drugs as Percentage over the previous financial year (30% weightage) | Highest of all entries received to have full marks and others proportionate | Expenditure on R&D related to Bulk Drugs for the last 2 financial years, duly certified by Company Secretary. |
A one page brief about the company along with a name of important products being produced and its therapeutic significance
3. India Pharma Innovation of the Year Award:
| S.No | Criteria | Indicators | Relevant information/ Documents to be furnished. |
| a | Number of patents files and commercialised during the last 3 financial years 1)No. of product patents filed -25% 2)No. of product patents granted-25% 3)No. of product patents commercialised- 25% 4)Percentage of patents /innovations commercialised during the last 3 financial years pertaining to NLEM drugs. (25% weightage) | Highest of all entries received to have full marks and others proportions to | No. of process and products patents filed during the last 3 financial years, duly certified by Company Secretary. No.of patents commercialised by the Company during the year duly certified by Company Secretary. No of patents, assigned to other entities in India and overseas, duly certified by Company Secretary |
A one page brief about the company along with a name of important products being produced and its therapeutic significance
4. India Pharma Corporate Social Responsibility (CSR) Programme of the Year Award:
| Relevant information/ Documents to be furnished | |
| - Details of CSR activities undertaken | Details of activities undertaken under Corporate Social Responsibility Total expenditure incurred on these activities for the last 3 years, duly certified by Company Secretary. Geographical coverage of the CSR activities and approximate impact on the number of people. |
| The Jury to decided |
A one page brief about the company along with a name of important products being produced and its therapeutic significance
Category 5- India Medical Devices Company of the Year Award
| S.No | Criteria | Indicators | Relevant information/ Documents to be furnished. |
| 1 | 2 | 3 | 4 |
| a. | Sales Turnover increase in % over the previous year (50% weightage) | - Percentage growth in Sales turnover over the previous year. Highest of all entries received to have full marks and others proportionate | Give details of the Medical Devices and their sales turnover during the last 2 years, duly certified by Company Secretary. Contents of different Medical Devices produced in terms of a value of content achieved. |
| b. | R&D expenditure as a % of Sales (50% weightage) | - The Percentage R&D expenditure on Sales turnover - Highest of all entries received to have full marks and other proportionate | R&D expenditure in terms of percentage of sales incurred during the last year, duly certified by Company Secretary. · Audited figures of expenditure on R&D in last year, duly certified by Company Secretary. |
A one page brief about the company along with a name of important products being produced
Category 6- India Pharma Swachhta Champion Award
The award would be open to all Pharma Industry, traders, Medical Devices Industry and their Associations in both rural & urban areas.
| S.No | Criteria | Indicators | Relevant information/ Documents to be furnished. |
| a. | Percentage of expenditure on Swachhata (including expenditure on waste disposal, making available drinking water, maintenance of toilets, display boards, hoardings on use of water, sanitation, hygiene etc) vis-a-vis total annual turnover (2018-19) (Weightage 20%) | Highest of all entries received to have full marks and others proportionate | Audited figures as per Annual Report, duly certified by the Company Secretary |
| b | Increase in expenditure on Swachhata (including expenditure on waste disposal, making available drinking water, maintenance of toilets, display boards, hoardings on use of water, sanitation, hygiene etc)in % terms over the previous year (Weightage 20%) | Highest of all entries received to have full marks and others proportionate | Audited figures as per Annual Report, duly certified by the Company Secretary |
| c | Percentage of Safai Karamchari (including persons deployed for waste disposal) vis a vis total employee of the unit (Weightage 10%) | Highest of all entries received to have full marks and others proportionate | As per the Annual Report of the company, duly; certified by the Company Secretary |
| d | Number of units of Gents toilets/urinals per 100 persons (Weightage 10%) | Highest of all entries received to have full marks and others proportionate | As per the Annual Report of the company, duly; certified by the Company Secretary |
| e | Number of units of Ladies toilets/urinals per 100 persons (Weightage 10%) | Highest of all entries received to have full marks and others proportionate | As per the Annual Report of the company, duly; certified by the Company Secretary |
| f | % Increase in the number of toilets/urinals constructed during 2018-19 over the previous year (Weightage 10%) | Highest of all entries received to have full marks and others proportionate | As per the Annual Report of the company, duly; certified by the Company Secretary |
| g | Number of dustbins installed per 100 persons (Weightage 10%) | Highest of all entries received to have full marks and others proportionate | As per the Annual Report of the company, duly; certified by the Company Secretary |
| h | Number of Drinking Water dispensers/RO per 100 persons (Weightage 10%) | Highest of all entries received to have full marks and others proportionate | As per the Annual Report of the company, duly; certified by the Company Secretary |
A one page brief about the company along with a name of important products being produced and its therapeutic significance.
The DoP release further added;
- Comparisons would be made based on audited results of the Financial Year 2018-19 and previous years
- Unaudited results would not be considered for evaluation
- No company would be conferred the Award in 2 categories in the same year. In case such a situation arises, the award appearing first in the list of the Awards would be conferred and the second award would be given to the applicant with the next highest marks.
- The same category of the award would not be conferred to the same company for 2 years in succession.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd